Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.822469/full |
| _version_ | 1811304163194175488 |
|---|---|
| author | YH Fan HX Ma SP Guo Y Chen SP Zhang |
| author_facet | YH Fan HX Ma SP Guo Y Chen SP Zhang |
| author_sort | YH Fan |
| collection | DOAJ |
| description | Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor. This report describes a 20 year-old man with PPES. After 4 neoadjuvant chemotherapy cycles (VACwith alternating IE) combined with anlotinib, the left total pneumonectomy was performed. Then maintenance anlotinib monotherapy was continued, no sign of recurrence to date as an outcome. To our knowledge, this is the first demonstration of anlotinib combined with neoadjuvant chemotherapy efficacy in PPES. |
| first_indexed | 2024-04-13T08:01:27Z |
| format | Article |
| id | doaj.art-5c148c26c21b44ddba137ccdd7ad70d6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T08:01:27Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-5c148c26c21b44ddba137ccdd7ad70d62022-12-22T02:55:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.822469822469Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case ReportYH Fan0 HX Ma1SP Guo2Y Chen3SP Zhang4Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of Operating Room Nursing, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaDepartment of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ChinaPrimary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor. This report describes a 20 year-old man with PPES. After 4 neoadjuvant chemotherapy cycles (VACwith alternating IE) combined with anlotinib, the left total pneumonectomy was performed. Then maintenance anlotinib monotherapy was continued, no sign of recurrence to date as an outcome. To our knowledge, this is the first demonstration of anlotinib combined with neoadjuvant chemotherapy efficacy in PPES.https://www.frontiersin.org/articles/10.3389/fonc.2022.822469/fullewing’s SarcomapulmonaryAnlotinibNeoadjuvant chemotherapymulti-targeted receptor tyrosine kinase |
| spellingShingle | YH Fan HX Ma SP Guo Y Chen SP Zhang Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report Frontiers in Oncology ewing’s Sarcoma pulmonary Anlotinib Neoadjuvant chemotherapy multi-targeted receptor tyrosine kinase |
| title | Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report |
| title_full | Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report |
| title_fullStr | Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report |
| title_full_unstemmed | Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report |
| title_short | Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report |
| title_sort | application of anlotinib combined with neoadjuvant chemotherapy in primary ews pnet of lung a case report |
| topic | ewing’s Sarcoma pulmonary Anlotinib Neoadjuvant chemotherapy multi-targeted receptor tyrosine kinase |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.822469/full |
| work_keys_str_mv | AT yhfan applicationofanlotinibcombinedwithneoadjuvantchemotherapyinprimaryewspnetoflungacasereport AT hxma applicationofanlotinibcombinedwithneoadjuvantchemotherapyinprimaryewspnetoflungacasereport AT spguo applicationofanlotinibcombinedwithneoadjuvantchemotherapyinprimaryewspnetoflungacasereport AT ychen applicationofanlotinibcombinedwithneoadjuvantchemotherapyinprimaryewspnetoflungacasereport AT spzhang applicationofanlotinibcombinedwithneoadjuvantchemotherapyinprimaryewspnetoflungacasereport |